Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-07-24, Stock:NVS, The news for the past five days is as follows:
2019-07-17: NEWS1: The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On.NEWS2: The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On.NEWS3: Pre-Market Earnings Report for July 18, 2019 :  UNH, HON, PM, UNP, DHR, MS, TSM, BBT, BX, NVS, STI, PPG.NEWS4: Pre-Market Earnings Report for July 18, 2019 :  UNH, HON, PM, UNP, DHR, MS, TSM, BBT, BX, NVS, STI, PPG.NEWS5: The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On.NEWS6: Why Earnings Season Could Be Great for Novartis (NVS).NEWS7: Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel.NEWS8: Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel.NEWS9: Merck's Antibiotic Recarbrio Gets FDA Nod for Infections.NEWS10: Merck's Antibiotic Recarbrio Gets FDA Nod for Infections.NEWS11: Why Earnings Season Could Be Great for Novartis (NVS).NEWS12: Merck's Antibiotic Recarbrio Gets FDA Nod for Infections.NEWS13: Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel.NEWS14: Trade Talk Cools Off Record-Setting Market.NEWS15: Should You Pick Up Novartis (NVS) Before Q2 Earnings?.NEWS16: Should You Pick Up Novartis (NVS) Before Q2 Earnings?.
2019-07-18: NEWS1: Novartis AG  (NVS) Q2 Earnings Call Transcript.NEWS2: Novartis AG  (NVS) Q2 Earnings Call Transcript.NEWS3: Pharma Giant Flirts With Record High As Copycat Drugs Gain Steam.NEWS4: Novartis AG (NVS) Q2 Earnings Call Transcript.NEWS5: Is a Beat in Store for Glaxo (GSK) This Earnings Season?.NEWS6: Is a Beat in Store for Glaxo (GSK) This Earnings Season?.NEWS7: Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance.NEWS8: Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance.NEWS9: Pharma Giant Flirts With Record High As Copycat Drugs Gain Steam.NEWS10: Is a Beat in Store for Glaxo (GSK) This Earnings Season?.NEWS11: Where Will Tilray Be in 5 Years?.NEWS12: Where Will Tilray Be in 5 Years?.NEWS13: [video]Novartis Up on Financial Results and Potential Resolution of Kickback Case.NEWS14: Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance.NEWS15: Stocks Stumble As Netflix Dives; Dow Jones Stock IBM Breaks Out, Apple Upgraded.NEWS16: Health Care Sector Update for 07/18/2019: CODX, IDXG, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS17: Health Care Sector Update for 07/18/2019: CODX, IDXG, NVS, JNJ, PFE, ABT, MRK, AMGN.NEWS18: Novartis Earnings Top; Swiss Drug Giant Soars.NEWS19: Pre-Market Most Active for Jul 18, 2019 :  NYMT, FDC, ERIC, NFLX, AMD, FISV, NOK, TVIX, ACB, NVS, TEVA, TOT.NEWS20: Pre-Market Most Active for Jul 18, 2019 :  NYMT, FDC, ERIC, NFLX, AMD, FISV, NOK, TVIX, ACB, NVS, TEVA, TOT.NEWS21: Stock Futures Dip As Netflix Drags On Nasdaq; eBay, Novartis Spike.NEWS22: Novartis raises full-year targets, aims to settle U.S. lawsuit.NEWS23: Novartis’s Brightened Outlook Pushes Shares to All-Time High.NEWS24: StockBeat: A Sea of Red as Earnings Live Down to Expectations.NEWS25: Novartis raises 2019 guidance, helped by Sandoz generics unit.
2019-07-19: NEWS1: Top Research Reports for Abbott, Netflix & Philip Morris.NEWS2: Top Research Reports for Abbott, Netflix & Philip Morris.NEWS3: Top Research Reports for Abbott, Netflix & Philip Morris.NEWS4: Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus.NEWS5: Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus.NEWS6: Novartis Posts Strong Earnings, but Is Mum on Sales of Its New Gene Therapy.NEWS7: Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus.NEWS8: Gilead licensing three pre-clinical programs from Novartis.NEWS9: Should You Go for the 'Easy Money' in Novartis?.
2019-07-22: NEWS1: The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis.NEWS2: The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis.NEWS3: The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis.
2019-07-23: NEWS1: Biogen downplays ‘premature’ talk of competition for SMA drug Spinraza.NEWS2: Biogen’s Good Quarter Delays Drugmaker’s Future Reckoning.NEWS3: Biogen’s Earnings Beat Forecasts, but 1 Key Drug Fell Short.NEWS4: The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis.NEWS5: The Zacks Analyst Blog Highlights: Abbott, Netflix, Philip Morris, United Technologies and Novartis.

Answer: Decrease